GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (NAS:ACST) » Definitions » Price-to-Tangible-Book

Acasti Pharma (Acasti Pharma) Price-to-Tangible-Book

: 1.74 (As of Today)
View and export this data going back to 2011. Start your Free Trial

As of today (2024-04-23), Acasti Pharma's share price is $2.85. Acasti Pharma's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.64. Hence, Acasti Pharma's Price to Tangible Book Ratio of today is 1.74.

The historical rank and industry rank for Acasti Pharma's Price-to-Tangible-Book or its related term are showing as below:

ACST' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.1   Med: 2.26   Max: 17.11
Current: 1.74

During the past 13 years, Acasti Pharma's highest Price to Tangible Book Ratio was 17.11. The lowest was 1.10. And the median was 2.26.

ACST's Price-to-Tangible-Book is ranked better than
67.08% of 1221 companies
in the Biotechnology industry
Industry Median: 2.67 vs ACST: 1.74

A closely related ratio is called PB Ratio. As of today, Acasti Pharma's share price is $2.85. Acasti Pharma's Book Value per Sharefor the quarter that ended in Dec. 2023 was $6.88. Hence, Acasti Pharma's P/B Ratio of today is 0.41.


Acasti Pharma Price-to-Tangible-Book Historical Data

The historical data trend for Acasti Pharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acasti Pharma Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Price-to-Tangible-Book
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.11 3.91 2.25 2.12 1.10

Acasti Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.60 1.10 1.59 1.50 1.76

Competitive Comparison

For the Biotechnology subindustry, Acasti Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acasti Pharma Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, Acasti Pharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Acasti Pharma's Price-to-Tangible-Book falls into.



Acasti Pharma Price-to-Tangible-Book Calculation

Acasti Pharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=2.85/1.64
=1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Acasti Pharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Acasti Pharma (Acasti Pharma) Business Description

Traded in Other Exchanges
Address
3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
Executives
George Kottayil director 49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540
A Brian Davis director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Edward Neugeboren director 282 NEW NORWALK ROAD, NEW CANAAN CT 06840
Vimal Kavuru director 11 MAACKA DRIVE, HOLMDEL NJ 07733
Donald Olds director 545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3
Amresh Kumar officer: VP Program Management 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Carrie D'andrea officer: VP Clinical Operations 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Prashant Kohli officer: Chief Executive Officer 206 CAMBRIDGE LANE, NEWTOWN PA 13940
R. Loch Macdonald officer: Chief Medical Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Michael Derby director 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
William A Haseltine director
Rajitha Grace 2018 Irrevocable Trust 10 percent owner 40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753
Swami Sambamurty Iyer 10 percent owner 20 TULSA COURT, MONMOUTH JUNCTION NJ 08852
Brian D. Ford officer: CHIEF FINANCIAL OFFICER 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
John Canan director C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202